VivoSim Labs, Inc. (VIVS)
$0.16-5.88%Close
SELLCRISIS · day 22
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $410,980
- Beta
- 1.49
- P/E (TTM)
- -0.03
- Short % float
- 30.91%
- Days to cover
- 1.0
- SI change
- +25.4%
- 1W
- -15.79%
- 1M
- -40.74%
- vs SPY 1W
- -15.65%
- vs SPY 1M
- -43.25%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 2
- GROWTH
- 29
- GARP
- 1
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-
REV YoY-
ROE-
EPS YoY-
ROA-320.7%
GROSS-135
OP-10117
NET-11016
[VALUATION]
P/E TTM-0.03
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B-0.36
P/FCF-
EV/EBITDA0.08
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO1.70
ND/EBITDA-
BETA1.49
NET INCOME (TTM) < 0
Company news
FAQ
- What is LOPJLB’s current signal on VIVS?
- LOPJLB’s latest quantitative signal on VivoSim Labs, Inc. (VIVS) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is VIVS in?
- VivoSim Labs, Inc. (VIVS) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does VivoSim Labs, Inc. (VIVS) do?
- VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action eluci…